248 related articles for article (PubMed ID: 9274991)
1. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
[TBL] [Abstract][Full Text] [Related]
2. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
3. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
4. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
[TBL] [Abstract][Full Text] [Related]
6. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
8. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.
Barbeis C; Balestre MN; Jard S; Tribollet E; Arsenijevic Y; Dreifuss JJ; Bankowski K; Manning M; Chan WY; Schlosser SS
Neuroendocrinology; 1995 Aug; 62(2):135-46. PubMed ID: 8584113
[TBL] [Abstract][Full Text] [Related]
10. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
12. 125I-d(CH2)5[Tyr(Me)2, Tyr(NH2)9]AVP: iodination and binding characteristics of a vasopressin receptor ligand.
Elands J; Barberis C; Jard S; Lammek B; Manning M; Sawyer WH; de Kloet ER
FEBS Lett; 1988 Mar; 229(2):251-5. PubMed ID: 2964381
[TBL] [Abstract][Full Text] [Related]
13. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
Croiset G; De Wied D
Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
[TBL] [Abstract][Full Text] [Related]
14. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
[TBL] [Abstract][Full Text] [Related]
15. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
Ammar A; Roseau S; Butlen D
Am J Physiol; 1992 Apr; 262(4 Pt 2):F546-53. PubMed ID: 1533099
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin and oxytocin receptors coupled to Ca2+ mobilization in rat inner medullary collecting duct.
Maeda Y; Han JS; Gibson CC; Knepper MA
Am J Physiol; 1993 Jul; 265(1 Pt 2):F15-25. PubMed ID: 8393622
[TBL] [Abstract][Full Text] [Related]
19. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
Yibchok-anun S; Hsu WH
Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
[TBL] [Abstract][Full Text] [Related]
20. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
Howl J; Prochazka Z; Wheatley M; Slaninová J
Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
